

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

Tracky unveils new platform to track patient outcomes for GLP-1 therapies

23 March 2026 | News

Enables pharma companies to build structured real-world evidence programmes



DrStore Healthcare Services, a connected healthcare and medical device ecosystem company, through its smart medical devices and tech platform Tracky, has launched an integrated, real-time monitoring platform designed to track patient outcomes for GLP-1 therapies in India.

The platform brings together multiple health data streams into a unified system, enabling clinicians and pharmaceutical companies to monitor therapy effectiveness, improve patient management, and generate real-world evidence.

The rapid rise of GLP-1 therapies for diabetes and weight management is reshaping the treatment landscape in India and globally. However, as adoption accelerates, a critical gap is becoming increasingly evident, the lack of continuous, structured data to monitor patient outcomes and understand therapy effectiveness in real-world settings.

Addressing this gap, Tracky is pioneering an integrated, real-time monitoring platform designed to bring together multiple health data streams into a unified, continuous view of patient health. The platform integrates glucose data from continuous glucose monitoring (CGM), Body composition tracking, Food logs & calorie tracking, activity levels, and wearable inputs, enabling longitudinal tracking and deeper insights into patient progress.

Within the context of GLP-1 therapies, it supports real-time tracking of patient progress, enabling clinicians to make more informed decisions around dosage titration, identify and manage side effects early, and monitor adherence to therapy.

By correlating these parameters with lifestyle and behavioral data, the platform also helps in understanding the sustainability of outcomes, supporting a more structured and data-driven approach to weight management during and after GLP therapy.

The platform also addresses a growing concern around GLP-1 treatments, the sustainability of outcomes after therapy discontinuation. While these therapies have shown strong clinical results, maintaining weight loss and metabolic improvements post-treatment remains a challenge. By combining continuous monitoring with lifestyle-linked insights, Tracky aims to support a more sustainable and data-driven approach to weight management, both during and beyond the therapy cycle.